Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma

NCT02133183 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

40

Enrollment

NIH

Sponsor class

Stopped Other - Lapse in funding

Conditions

Glioblastoma
Gliosarcoma

Interventions

OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Sapanisertib
PROCEDURE: Therapeutic Conventional Surgery

Sponsor

National Cancer Institute (NCI)